AWARD NUMBER: W81XWH-07-1-0578

TITLE: Understanding the Mechanisms of Platelet Alloimmunization and Its Prevention

PRINCIPAL INVESTIGATOR: Sherrill J. Slichter, M.D.
Karen A. Nelson, Ph.D.
Yvette E. Latchman, Ph.D.
Lakshmi Gaur, Ph.D.

CONTRACTING ORGANIZATION: Puget Sound Blood Center
Seattle, WA 98104

REPORT DATE: September 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
1. REPORT DATE
1 September 2010

2. REPORT TYPE
Annual

3. DATES COVERED
1 Sep 2009 - 31 Aug 2010

4. TITLE AND SUBTITLE
Understanding the Mechanisms of Platelet Alloimmunization and Its Prevention

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-07-1-0578

5c. PROGRAM ELEMENT NUMBER

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

6. AUTHOR(S)
Sherrill J. Slichter, M.D.
Lakshmi Gaur, Ph.D.
E-Mail: sjslichter@psbc.org

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Puget Sound Blood Center
Seattle, WA 98105

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR’S ACRONYM(S)

11. SPONSOR/MONITOR’S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
We have used a dog platelet transfusion model to evaluate methods of preventing alloimmune platelet refractoriness. Our initial hypothesis was that filtration-leukoreduction, when combined with y-irradiation, would prevent alloimmunization. However, this approach was successful in only 2/11 recipient dogs (18%). Over the past year, we have switched our approach to determine if a pathogen reduction process involving adding riboflavin to the platelets followed by UV-irradiation (mirasol technology), when combined with filtration leukoreduction, would be successful. We have been able to prevent alloimmune platelet refractoriness using this approach in 13/14 (93%) of recipient dogs.

15. SUBJECT TERMS
Platelets, Platelet Transfusion, Leukoreduction, y-Irradiation, UV-Irradiation, Alloimmunization, Tolerance

16. SECURITY CLASSIFICATION OF:
a. REPORT U
b. ABSTRACT U
c. THIS PAGE U

17. LIMITATION OF ABSTRACT
UU

18. NUMBER OF PAGES
8

19a. NAME OF RESPONSIBLE PERSON
USAMRMC

19b. TELEPHONE NUMBER (include area code)
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report Document Front Cover Page</td>
<td>1</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>2</td>
</tr>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>6</td>
</tr>
<tr>
<td>Conclusion</td>
<td>6</td>
</tr>
<tr>
<td>References</td>
<td>6</td>
</tr>
<tr>
<td>Appendices:</td>
<td></td>
</tr>
<tr>
<td>Appendix 1</td>
<td>7</td>
</tr>
</tbody>
</table>
INTRODUCTION:

Over the last year, we have evaluated a pathogen-reduction process which is able to inactivate antigen-presenting white cells to determine whether this technology, when used alone or combined with filtration leukoreduction, would be able to prevent alloimmune platelet refractoriness in our dog platelet transfusion model. We have collaborated in these studies with the CaridianBCT Corporation which adds riboflavin (Vitamin B2) to the platelets and then exposes the platelets to UV-light (Mirasol Technology). This process prevents replication of DNA and RNA in viruses, bacteria, and WBCs and has been shown to inactivate a broad range of pathogens as well as prevent transfusion-associated graft-versus-host disease eliminating the need for γ-irradiation of transfused blood products.

BODY:

Methods.

Experimental Design of the Platelet Transfusion Experiments.
1) Select crossmatch negative and DLA-DRB mismatched donor/recipient pairs.
2) Platelets are obtained weekly from a single random donor.
3) Donor dog’s platelets are unmodified (standard), filter-leukoreduced, γ-irradiated, addition of Vitamin B2 to the platelets plus UV-irradiation (Mirasol technology), or treatments are combined.
4) Donor dog’s platelets are radiochromium labeled prior to recipient transfusion.
5) Serial blood samples are drawn from the recipient to determine recovery and survival of the donor dog’s platelets.
6) Baseline and weekly blood samples are drawn to identify IgM and IgG antibodies to donor platelets and WBCs. Samples are also tested against autologous platelets and WBCs as a negative control. Antisera from alloimmune platelet refractory animals are pooled and run as a positive control against both autologous and allogeneic platelets and WBCs.
7) Recipient receives up to 8 weekly transfusions from their donor or until they become platelet refractory.
8) Primary Endpoint: Platelet refractoriness is defined as ≤5% of the radiolabeled donor dog’s platelets still circulating in the recipient at 24 hours post-transfusion after two sequential transfusions.
9) Autologous radiolabeled platelet recovery and survival measurements are performed baseline and at the end of each study. These measurements are done to ensure that refractoriness to donor transfusions is caused by alloimmunization rather than by some condition in the transfused recipient that would affect the recovery and survival of both their allogeneic as well as their autologous platelets.

Preparation of Donor Platelets.
The methods outlined can be used alone or can be combined by both filtering and irradiating the donor’s platelet-rich plasma before preparation and injection of the donor’s platelet concentrate.

Results.

Table 1 shows the number of recipient dogs who accepted 8 weeks of standard or single modified platelet transfusions from their donor dogs. Standard platelets (unmodified platelets) were accepted by only 1/7 (14%) of the recipient dogs. We evaluated two different leukoreduction filters, and one of them (PL1B) was no more successful than the standard platelet transfusions; i.e., 1/5 recipients (20%) accepted donor platelets. However, the other filter (PLS-5A) resulted in donor platelets being accepted by 4/6 (66%) of the recipients, and all 6 dogs accepted at least 6 weeks of donor platelets before two dogs became refractory after 6 and 7 donor transfusions (Figure 1). Unfortunately, neither Mirasol treatment nor γ-irradiation were successful in preventing platelet refractoriness; i.e., 1/8 (13%) and 0/5 (0%) recipients accepted donor platelets.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Table 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SINGLE PLATELET MODIFICATIONS</strong></td>
<td><strong>COMBINED PLATELET MODIFICATIONS:</strong> FILTER LEUKOREDUCTION PLUS γ-IRRADIATION OR MIRASOL TREATMENT</td>
</tr>
<tr>
<td>Standard (Unmodified Platelets)</td>
<td>FILTER LEUKOREDUCTION PLUS γ-IRRADIATION OR MIRASOL TREATMENT</td>
</tr>
<tr>
<td># Donors Accepted / # Recipients (%)</td>
<td>Filtration</td>
</tr>
<tr>
<td>Filtration:</td>
<td>γ-IRRADIATION</td>
</tr>
<tr>
<td>• Pall PL1B Filter</td>
<td>• Pall PL1B*</td>
</tr>
<tr>
<td>1 / 5 (20%)</td>
<td>0 / 5 (0%)</td>
</tr>
<tr>
<td>• Fenwal PLS-5A Filter</td>
<td>• Fenwal PLS-5A++</td>
</tr>
<tr>
<td>4 / 6 (66%)</td>
<td>2 / 6 (33%)</td>
</tr>
<tr>
<td>Mirasol Treatment</td>
<td>Total</td>
</tr>
<tr>
<td>1 / 8 (13%)</td>
<td>2 / 11 (18%)</td>
</tr>
<tr>
<td>γ-Irradiation</td>
<td>6 / 11 (100%)</td>
</tr>
<tr>
<td>0 / 5 (0%)</td>
<td><strong>MIRASOL TREATMENT</strong></td>
</tr>
<tr>
<td>13 / 14 (93%)</td>
<td>p=0.005</td>
</tr>
</tbody>
</table>

We then evaluated the platelet transfusion results when either γ-irradiation or Mirasol treatment were combined with the two filters (Table 2). As can be seen, γ-irradiation did not improve the results achieved with either filter, while Mirasol treatment was 100% successful when used with the poorly-performing PL1B filter (6/6 recipients accepted donor platelets) and was successful in 7/8 (88%) of recipients when used with the PLS-5A filter. Overall, 2/11 (18%) of recipients accepted F-LR γ-irradiated platelets compared to 13/14 (93%) of recipients who accepted F-LR/Mirasol treated platelets (p=0.005). Figure 2 shows the time to refractoriness for the combined treatment programs.

**KEY RESEARCH ACCOMPLISHMENTS:**

The observation that combining F-LR with a pathogen reduction technology is almost completely successful in preventing alloimmune platelet refractoriness represents a major breakthrough in our...
understanding of how to prevent this adverse event. We know that F-LR does not remove all antigen-presenting WBCs. F-LR may remove enough WBCs to allow the remaining WBCs to be effectively inactivated using the Mirasol technology allowing the combined approach to be successful. The fact that this combined approach is effective even with a poorly performing filter may suggest that this combined approach may be successful when used with any available filter.

It cannot be emphasized enough the many advantages of this combined approach for transfused recipients in addition to preventing alloimmunization. Leukoreduction prevents CMV transmission by transfusion, reduces cytokine reactions from WBC breakdown during storage, and prevents febrile transfusion reactions. Pathogen reduction inactivates bacteria, viruses, and other transfusion-transmissible agents, may prevent the introduction of the next unknown pathogen into the blood supply, and can eliminate the need for γ-irradiation of blood products to prevent transfusion associated graft-versus-host disease.

REPORTABLE OUTCOMES:
Please refer to the attached abstract which has been accepted as a poster presentation at the annual American Society of Hematology meeting in December 2010.

CONCLUSION:
• Different filters have different alloimmunization rates, possibly related to the WBCs they remove versus those that remain following filtration.
• Neither γ-irradiation nor pathogen-reduction (Mirasol technology) are able to prevent platelet alloimmunization.
• γ-irradiation does not increase acceptance of F-LR platelets.
• Mirasol treatment plus F-LR is almost completely effective in preventing alloimmune platelet refractoriness.
• If Mirasol-treated/F-LR platelets were given to immunosuppressed patients, it is anticipated that alloimmunization would be completely prevented.

REFERENCES:
None.

APPENDICES:
Appendix 1: 2010 American Society of Hematology Abstract:
APPENDIX 1

Prevention of Alloimmune Platelet (Pit) Refractoriness In a Dog Model Requires Both Removal and Inactivation of Contaminating Donor White Blood Cells (WBCs)

Sherrill J. Slichter, MD, Esther Pellham, BS, MBA, S. Lawrence Bailey, BS, Todd Christoffel, MT(ASCP), Lakshmi Gaur, PhD, Yvette Latchman, PhD, Karen Nelson, PhD, and Doug Bolgiano, MS

Puget Sound Blood Center, Seattle, WA; Puget Sound Blood Ctr. and Program, Seattle, WA

Background: The TRAP Trial (NEJM 1997;337:1861) evaluated filtration leukocyte-reduction (F-LR) and UV-B irradiation (UV-BI) to prevent pit alloimmunization in AML patients (pts) receiving chemotherapy. Inclusion of UV-BI was based on a 45% rate of preventing pit alloimmunization in our dog pit tx model. UV-BI was 79% successful in the TRAP Trial. The lower success rate in the dog was probably because we use normal immunocompetent recipient dogs versus chemotherapy-induced immunosuppressed pts. The residual rate of alloimmunization in the TRAP Trial using either F-LR or UV-BI was still 17% to 21%, suggesting that better prevention methods are needed.

Methods: In our dog pit tx model, we evaluated two leukoreduction filters to remove antigen presenting WBCs (APCs) and γ-irradiation (γ-I) or UV-I combined with riboflavin (Mirasol pathogen reduction technology) to inactivate APCs. Crossmatch-negative, DLA-DRB incompatible donor/recipient pairs were used. Txs from the same donor were given weekly for up to 8 weeks or until the donor's 51Cr-labeled pits were rejected based on two sequential txs with donor pit recoveries ≤5% at 20 hours post-tx.

Results

<table>
<thead>
<tr>
<th>Platelet Modification</th>
<th># Donors Accepted / # Recipients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>1 / 7 (14%)</td>
</tr>
<tr>
<td>Single Modification:</td>
<td></td>
</tr>
<tr>
<td>F-LR:</td>
<td></td>
</tr>
<tr>
<td>Pall PL1-B Filter</td>
<td>1 / 5 (20%)</td>
</tr>
<tr>
<td>Fenwal PLS-5A Filter</td>
<td>4 / 6 (66%)</td>
</tr>
<tr>
<td>γ-I</td>
<td>0 / 5 (0%)</td>
</tr>
<tr>
<td>Mirasol Treatment</td>
<td>1 / 8 (13%)</td>
</tr>
<tr>
<td>Combined Modifications:</td>
<td></td>
</tr>
<tr>
<td>F-LR plus γ-I:</td>
<td></td>
</tr>
<tr>
<td>PL1-B Filter</td>
<td>0 / 5 (0%)</td>
</tr>
<tr>
<td>PLS-5A Filter</td>
<td>2 / 6 (33%)</td>
</tr>
<tr>
<td>Total*</td>
<td>2 / 11 (18%)</td>
</tr>
<tr>
<td>F-LR plus Mirasol Treatment:</td>
<td></td>
</tr>
<tr>
<td>PL1-B Filter</td>
<td>6 / 6 (100%)</td>
</tr>
<tr>
<td>PLS-5A Filter</td>
<td>7 / 8 (88%)</td>
</tr>
<tr>
<td>Total*</td>
<td>13 / 14 (93%)</td>
</tr>
</tbody>
</table>

*F-LR plus Mirasol-treated plts had a total success rate of 93% versus F-LR, γ-I plts at 18% (p=0.005).

Residual WBC counts for standard, γ-I, or Mirasol-treated plts averaged 2,860/μl ± 1,800/μl, and, for F-LR plts using the PL1-B or the PLS-5A filter, they were 80/μl ± 10/μl and 110/μl ± 270/μl, respectively. Residual WBCs were significantly reduced after F-LR compared to non-leukoreduced plts (p<0.001), but there was no significant difference for WBC removal using either filter (p=0.86).
Figure 1 shows the time to alloimmune pit refractoriness for recipients of single modified pits either F-LR, γ-I, or Mirasol-treated, while Figure 2 shows similar data for dogs who received F-LR pits combined with either γ-I or Mirasol treatment. Conclusions: Except for the results with the PLS-5A filter, a single modification of the donor dog's pits is only minimally successful. Although residual WBC counts were similar for both filters, the better results achieved with the PLS-5A filter compared to the PL1-B filter (66% versus 20% success rate, respectively) suggest that the types of WBCs removed may be as important as simply a quantitative reduction in WBCs. Unfortunately, adding γ-I to F-LR did not improve the results using either filter. In contrast, Mirasol treatment markedly improved the results with both filters, suggesting that the effects of F-LR and Mirasol treatment are synergistic with F-LR removing APCs, while Mirasol treatment inactivates residual APCs. The effect is particularly striking for the PL1-B filter that is only minimally effective when used alone. The fact that a combined F-LR Mirasol treatment approach is so successful in our immunocompetent dog model using both good and poor performing filters may suggest two things: 1) the combined approach will be equally successful in both immunosuppressed as well as non-immunosuppressed pts; and 2) using any available leukoreduction filter combined with Mirasol treatment will give results similar to the two filters already tested. Based on our prior experience with UV-BI, data from our dog model may be directly transferable to man.